Paul Brett

Paul Brett is a Professor in the Department of Microbiology and Immunology at the University of Nevada, Reno School of Medicine. With over 25 years of experience researching Burkholderia pseudomallei, the causative agent of melioidosis, Dr. Brett leads a laboratory focused on understanding molecular mechanisms of bacterial pathogenesis and developing effective vaccines against this significant infectious disease.

Dr. Brett received his B.Sc. in Biochemistry from the University of Victoria and his Ph.D. in Bacterial Pathogenesis from the University of Calgary. His academic credentials have supported a distinguished career investigating bacterial virulence mechanisms, particularly focusing on how B. pseudomallei evades host immune defenses through specialized surface structures.

Dr. Brett's research program centers on elucidating how lipopolysaccharides and capsular polysaccharides expressed by B. pseudomallei contribute to immune evasion. His laboratory has developed significant expertise in carbohydrate purification/characterization, glycoconjugate synthesis, and comprehensive analysis of humoral/cellular immune responses. The ultimate goal of his research is to identify correlates of antigen-induced immunity against B. pseudomallei to develop safe, affordable, and effective melioidosis vaccines that could address this serious public health threat.

Analysis of Dr. Brett's publication history reveals a consistent research trajectory with publications spanning from the early 2000s through 2025. His work demonstrates increasing sophistication in vaccine development approaches, with recent publications focusing on glycoconjugate vaccines, structural analysis of bacterial components, and innovative diagnostic methods for melioidosis. His research bridges molecular microbiology and translational immunology, with direct applications to vaccine design and development.

Dr. Brett has participated in significant collaborative efforts, including the Melioidosis Diagnostic Workshop in 2013 and the Steering Group on Melioidosis Vaccine Development. These collaborations highlight his standing as a recognized expert in the field and his commitment to advancing international efforts to combat melioidosis.

Though specific details about current students and grants are not provided in the available materials, Dr. Brett's active publication record through 2025 and his laboratory's described capabilities suggest he maintains a vibrant research program with ongoing funding and mentorship of graduate students and postdoctoral researchers. His work has direct relevance to both public health initiatives in melioidosis-endemic regions and biodefense preparedness efforts given B. pseudomallei's classification as a Tier 1 select agent.